Glyscend Therapeutics
Developer of oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes, and other chronic conditions. The company is developing a lead drug, which is orally administered, non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety-advantages avoiding invasive complications of surgeries and procedures.
7-day free trial · no credit card
Verified contacts
6
available on Kipplo
LinkedIn employees
8
11 to 50 range
Open roles
—
no listings
Distinct roles
6
indexed titles
Tech stack
1
tools in use
Monthly traffic
24
organic / mo
Sign up free to see all 6 verified contacts at Glyscend Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
6 contacts with verified email or phone · masked until revealed.
- SS
Sapan Shah
Chief Executive Officer · General Business & Management
EmailPhone - CB
Christine Bryant
Sr Director of Clinical and Translational Science · Other
EmailPhone - BS
Bob Sacchiero
Independent Consultant · General Business & Management
EmailPhone - KC
Kevin Colbert
Biomedical Engineering Med Device Operations · Operations
EmailPhone - SM
Sarah McHugh
Senior Project Manager Consultant · General Business & Management
EmailPhone
Showing 5 of 6 verified contacts
Top roles at Glyscend Therapeutics
6 distinct titles indexed · top 6 shown.
- 1biomedical engineering med device operations
- 1chief executive officer
- 1independent consultant
- 1research and development intern
- 1senior project manager consultant
- 1sr director of clinical and translational science
Sign up to unlock all 6 contacts at Glyscend Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 6 verified contacts at Glyscend Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.